Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.99 USD | -1.03% | -0.29% | -0.36% |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.94B | Capitalization | 12.62B |
---|---|---|---|---|---|
Net income 2024 * | 1.05B | Net income 2025 * | 1.08B | EV / Sales 2024 * | 6.91 x |
Net Debt 2024 * | 5.75B | Net Debt 2025 * | 5.94B | EV / Sales 2025 * | 6.31 x |
P/E ratio 2024 * |
12
x | P/E ratio 2025 * |
11.5
x | Employees | - |
Yield 2024 * |
3.16% | Yield 2025 * |
3.42% | Free-Float | 95.13% |
Latest transcript on Royalty Pharma plc
1 day | -1.03% | ||
1 week | -0.29% | ||
Current month | +1.05% | ||
1 month | -4.27% | ||
3 months | -2.47% | ||
6 months | +1.34% | ||
Current year | -0.36% |
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 09-12-31 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 95-12-31 |
Errol de Souza
BRD | Director/Board Member | 70 | 20-05-31 |
David Hodgson
BRD | Director/Board Member | 67 | 22-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.98% | 0 M€ | +12.09% | - | |
0.51% | 5 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 27.99 | -1.03% | 3,493,978 |
24-05-07 | 28.28 | -0.74% | 2,949,021 |
24-05-06 | 28.49 | +0.28% | 1,860,977 |
24-05-03 | 28.41 | -1.22% | 2,169,369 |
24-05-02 | 28.76 | +2.46% | 5,351,633 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.36% | 12.62B | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.82% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- RPRX Stock